Israel Health News API

{
    "totalArticles": 11246,
    "articles": [
        {
            "id": "6a1e47c1cca103713c3ceb7fee9d0514",
            "title": "5 מזונות ותוספים שחייבים בחורף כדי לחזק את המערכת החיסונית",
            "description": "המומחים מציעים דרכים פשוטות לחיזוק הגוף בחורף: ויטמין D, ברזל מהמזון, חמאת בוטנים טבעית, כורכום ומגנזיום ושומשום שחור – ללא פתרונות מסובכים",
            "content": "כדי לחזק את הגוף בעונת החורף, מומחים מציעים לא להסתמך רק על ויטמין C, אלא גם על תוספי תזונה ומזונות שמסייעים למערכת החיסון ולבריאות הכללית, כך לפי ידיעה שהובאה ב\"אל ערבייה\".\nחמאת בוטנים איכותית תכיל כמה שפחות רכיבים. מומלץ להימנע ממוצרים עם סוכר או מ... [709 chars]",
            "url": "https://www.maariv.co.il/news/viral/article-1276104",
            "image": "https://images.maariv.co.il/image/upload/f_auto,fl_lossy/c_fill,g_faces:center,w_1200/940894",
            "publishedAt": "2026-01-22T21:10:15Z",
            "lang": "he",
            "source": {
                "id": "0c6f11b41203735f78e10491117fe247",
                "name": "מעריב",
                "url": "https://www.maariv.co.il"
            }
        },
        {
            "id": "e8d6003b4bdf98070ab04a0e838e3853",
            "title": "Ocular Symptoms, Malignancy Common in Double Seronegative MG",
            "description": "A review of case studies found that patients with double seronegative myasthenia gravis (MG) had similarities in the ways their condition presented.",
            "content": "Patients with double seronegative myasthenia gravis (dSNMG) had similar clinical characteristics across the board, according to a review published in BMC Neurology.1 Ocular symptoms and malignancy were the most common characteristics reported, highli... [3375 chars]",
            "url": "https://www.ajmc.com/view/ocular-symptoms-malignancy-common-in-double-seronegative-mg",
            "image": "https://cdn.sanity.io/images/0vv8moc6/ajmc/c562bb498b85ec409566f54afe0f5211f011b11c-5616x3744.jpg",
            "publishedAt": "2026-01-22T20:06:16Z",
            "lang": "en",
            "source": {
                "id": "44c3dc8c76228ef5cb2e596d2bd52f75",
                "name": "The American Journal of Managed Care® (AJMC®)",
                "url": "https://www.ajmc.com"
            }
        },
        {
            "id": "215c676da6db78f9360a29d550e88132",
            "title": "Rocatinlimab Demonstrates Significant Efficacy and Safety in Phase 3 Trials for Moderate-to-Severe Atopic Dermatitis",
            "description": "Rocatinlimab shows promise in treating moderate-to-severe atopic dermatitis, offering significant symptom relief.",
            "content": "In the 2 global, double-blind, placebo-controlled, randomized phase 3 ROCKET-IGNITE (IGNITE; NCT05398445) and ROCKET-HORIZON (HORIZON; NCT05651711) clinical trials, rocatinlimab (Amgen and Kyowa Kirin) demonstrated lasting benefits for the treatment ... [4813 chars]",
            "url": "https://www.pharmacytimes.com/view/rocatinlimab-demonstrates-significant-efficacy-and-safety-in-phase-3-trials-for-moderate-to-severe-atopic-dermatitis",
            "image": "https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/90825a04063b3fd08f67c906457f9cd21672029d-6000x4000.jpg",
            "publishedAt": "2026-01-22T20:05:06Z",
            "lang": "en",
            "source": {
                "id": "3a4e8bd2a12cbc70d635a30cfc733690",
                "name": "Pharmacy Times",
                "url": "https://www.pharmacytimes.com"
            }
        }
    ]
}